Kataja M, et al. - This paper incorporated an analysis of the anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration in the real-life scenario. Furthermore, the authors compared the incidence of ocular serious adverse events after injections administered by nurses and physicians. The observation made was that the visual acuity was maintained at the baseline level (±0 letters) with the mean of 15.3 anti-VEGF injections in the clinical practice, during a 3-year follow-up.